Elga Esposito

Dr. Elga Esposito

Harvard Medical School, Massachusetts General Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
ELEster Licastro
Ester Licastro
GPGIUSEPPE PIGNATARO
GIUSEPPE PIGNATARO
JIJeffrey J. Iliff
Jeffrey J. Iliff
YXYanxiao Xiang
Yanxiao Xiang
ELEng Lo
Eng Lo
Elga EspositoElga Esposito
Elga Esposito
Crosstalk between central nervous system (CNS) and systemic responses is important in many pathological conditions, including stroke, neurodegeneration, schizophrenia, epilepsy, etc. Accumulating evidence suggest that signals for central-systemic crosstalk may utilize glymphatic and lymphatic pathways. The glymphatic system is functionally connected to the meningeal lymphatic system, and together these pathways may be involved in the distribution of soluble proteins and clearance of metabolites and waste products from the CNS. Lymphatic vessels in the dura and meninges transport cerebrospinal fluid, in part collected from the glymphatic system, to the cervical lymph nodes, where solutes coming from the brain (i.e., VEGFC, oligomeric α-syn, β-amyloid) might activate a systemic inflammatory response. There is also an element of time since the immune system is strongly regulated by circadian rhythms, and both glymphatic and lymphatic dynamics have been shown to change during the day and night. Understanding the mechanisms regulating the brain-cervical lymph node (CLN) signaling and how it might be affected by diurnal or circadian rhythms is fundamental to find specific targets and timing for therapeutic interventions.

23 March 2018 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
Elga EspositoElga Esposito
Elga Esposito
KHKazuhide Hayakawa
Kazuhide Hayakawa
BABum Ju Ahn
Bum Ju Ahn
SCSu Jing Chan
Su Jing Chan
CXChanghong Xing
Changhong Xing
ELEng Lo
Eng Lo

1 September 2015 in Stroke
Verified
Journal Article
Closed access
PDF file
Elga EspositoElga Esposito
Elga Esposito
KHKazuhide Hayakawa
Kazuhide Hayakawa
TMTakakuni Maki
Takakuni Maki
KAKen Arai
Ken Arai
ELEng Lo
Eng Lo
Background and Purpose—: Postconditioning may be a clinically feasible way to protect the brain after a stroke. However, its effects during the recovery phase post stroke remain to be fully elucidated. Here, we examine the hypothesis that ischemic postconditioning amplifies neurogenesis and angiogenesis during stroke recovery. Methods—: Male Sprague–Dawley rats were subjected to 100-minute transient middle cerebral artery occlusion (MCAO) or postconditioning (100-minute middle cerebral artery occlusion plus 10-minute reperfusion plus 10-minute reocclusion). After 2 weeks, infarct volumes, behavioral outcomes, and immunohistochemical markers of neurogenesis and angiogenesis were quantified. Results—: Postconditioning significantly reduced infarction and improved neurological outcomes. Concomitantly, brains subjected to postconditioning showed an increase in doublecortin/BrdU and collagen-IV/Ki67-positive cells. Conclusions—: These results suggest that therapeutic effects of postconditioning may involve the promotion of neurogenesis and angiogenic remodeling during the recovery phase after focal cerebral ischemia.

1 December 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
Elga EspositoElga Esposito
Elga Esposito
FZFang Zhang
Fang Zhang
JPJi-Hyun Park
Ji-Hyun Park
Emiri T. MandevilleEmiri T. Mandeville
Emiri T. Mandeville
Wenlu LiWenlu Li
Wenlu Li
ELEng Lo
Eng Lo
Background: The immune response to acute cerebral ischemia is a major factor in stroke pathobiology. Circadian biology modulates some aspects of immune response. The goal of this study is to compare key parameters of immune response during the active/awake phase versus inactive/sleep phase in a mouse model of transient focal cerebral ischemia. Methods: Mice were housed in normal or reversed light cycle rooms for 3 weeks, and then they were blindly subjected to transient focal cerebral ischemia. Flow cytometry was used to examine immune responses in blood, spleen, and brain at 3 days after ischemic onset. Results: In blood, there were higher levels of circulating T cells in mice subjected to focal ischemia during zeitgeber time (ZT)1–3 (inactive or sleep phase) versus ZT13–15 mice (active or awake phase). In the spleen, organ weight and immune cell numbers were lower in ZT1–3 versus ZT13–15 mice. Consistent with these results, there was an increased infiltration of activated T cells into brain at ZT1–3 compared with ZT13–15. Conclusions: This proof-of-concept study indicates that there are significant diurnal effects on the immune response after focal cerebral ischemia in mice. Hence, therapeutic strategies focused on immune targets should be reassessed to account for the effects of diurnal rhythms and circadian biology in nocturnal rodent models of stroke.

16 January 2026 in Circulation Research
Verified
Journal Article
Open access
SVSandra Vázquez-Reyes
Sandra Vázquez-Reyes
AGAlicia García-Culebras
Alicia García-Culebras
GDGaohong Di
Gaohong Di
FCFrancisco J. De Castro-Millán
Francisco J. De Castro-Millán
BBBlanca Díaz Benito
Blanca Díaz Benito
MMMaría Ángeles Moro
María Ángeles Moro
BACKGROUND: Stroke remains a leading cause of mortality and disability, driven by complex, time-dependent mechanisms that aggravate ischemic injury. Collateral perfusion dictates infarct size, expansion rate, and penumbral preservation, yet its regulation is poorly understood. Beyond structural/genetic factors such as aging or cardiovascular risk, functional influences like circadian immune activity may also affect vascular patency. Neutrophils, key mediators of ischemic injury, exhibit circadian oscillations in phenotype and function that could modulate collateral flow and stroke outcome. METHODS: We combined permanent and transient middle cerebral artery occlusion models in mice with flow cytometry, single-cell RNA sequencing, confocal microscopy, and laser speckle imaging to investigate time-of-day–dependent neutrophil mechanisms in stroke. Pharmacological (chloramidine, DNase-I) and genetic (Pad4 [peptidyl arginine deiminase 4] −/ − , Bmal1 [brain and muscle ARNT (aryl hydrocarbon receptor nuclear translocator)-like 1] Neu , Cxcr4 [C-X-C chemokine receptor type 4] Neu ) interventions were used to define how time-of-day regulation shapes neutrophil function, neutrophil extracellular traps (NETs) formation, and stroke severity. A cohort of 540 patients with ischemic stroke was analyzed for diurnal patterns of NET-related biomarkers and their association with collateral circulation and clinical outcomes. RESULTS: Infarct volume and neurological deficits exhibited clear circadian oscillations, with worse outcomes when stroke occurred during the murine inactive phase (Zeitgeber time 5) versus the active phase (Zeitgeber time 13). These fluctuations disappeared after neutrophil depletion or clock disruption. During the inactive phase, neutrophils displayed an activated, NET-prone phenotype, causing microvascular stalling and reduced collateral perfusion. Inhibiting NET formation pharmacologically or through Pad4 deletion restored perfusion and abolished time-of-day effects. In patients, neutrophil and NET-related biomarkers (MPO [myeloperoxidase], elastase, sCD40L [soluble CD40 ligand]) showed diurnal oscillations, peaking during the human inactive phase (evening/night), coinciding with reduced collateral flow and poorer outcomes. CONCLUSIONS: Time-of-day regulation of neutrophil function critically determines collateral perfusion and stroke severity. Neutrophil-driven NETosis during the inactive phase promotes microvascular obstruction and worsens outcomes. Targeting NET formation or timing therapy could enhance collateral efficacy and offer novel chronotherapeutic opportunities for stroke treatment.

1 December 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
Emiri T. MandevilleEmiri T. Mandeville
Emiri T. Mandeville
Wenlu LiWenlu Li
Wenlu Li
DQDavid Quinto-Alemany
David Quinto-Alemany
FZFang Zhang
Fang Zhang
Elga EspositoElga Esposito
Elga Esposito
ELEng Lo
Eng Lo
Background: It has been reported that the S1P (sphingosine 1-phosphate) receptor modulator fingolimod reduces infarction in rodent models of stroke. Recent studies have suggested that circadian rhythms affect stroke and neuroprotection. Therefore, this study revisited the use of fingolimod in mouse focal cerebral ischemia to test the hypothesis that efficacy might depend on whether experiments were performed during the inactive sleep or active wake phases of the circadian cycle. Methods: Two different stroke models were implemented in male C57Bl/6 mice—transient middle cerebral artery occlusion and permanent distal middle cerebral artery occlusion. Occlusion occurred either during inactive or active circadian phases. Mice were treated with 1 mg/kg fingolimod at 30- or 60-minute postocclusion and 1 day later for permanent and transient middle cerebral artery occlusion, respectively. Infarct volume, brain swelling, hemorrhagic transformation, and behavioral outcome were assessed at 2 or 3 days poststroke. Three independent experiments were performed in 2 different laboratories. Results: Fingolimod decreased peripheral lymphocyte number in naive mice, as expected. However, it did not significantly affect infarct volume, brain swelling, hemorrhagic transformation, or behavioral outcome at 2 or 3 days after transient or permanent focal cerebral ischemia during inactive or active circadian phases of stroke onset. Conclusions: Outcomes were not improved by fingolimod in either transient or permanent focal cerebral ischemia during both active and inactive circadian phases. These negative findings suggest that further testing of fingolimod in clinical trials may not be warranted unless translational studies can identify factors associated with fingolimod’s efficacy or lack thereof.